Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
New England Journal of Medicine · 23.01.2025 · 392 (4) · 361-371
DOI: 10.1056/nejmoa2406674 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 23.01.2025. Verfasst von Christian T Ruff und 19 weiteren Autor:innen. Beteiligte Einrichtung: From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston (C.T.R., S.M.P., R.P.G.,…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Anticoagulants, Atrial Fibrillation, Factor Xa Inhibitors. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Anthos Therapeutics.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston (C.T.R., S.M.P., R.P.G., D.A.M., J.F.K., E.L.G., S.A.M., S.D.W., M.S.S.); Anthos Therapeutics,…
ORCID-Profile: Siddharth M Patel, Boyoung Joung
Förderung
- Anthos Therapeutics
Zitieren
APA
Ruff, C. T., Patel, S. M., Giugliano, R. P., Morrow, D. A., Hug, B., Kuder, J. F., Goodrich, E. L., Chen, S. A., Goodman, S. G., Joung, B., Kiss, R. G., Spinar, J., Wojakowski, W., Weitz, J. I., Murphy, S. A., Wiviott, S. D., Parkar, S., Bloomfield, D., Sabatine, M. S., & AZALEA–TIMI 71 Investigators (2025). Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. New England Journal of Medicine, 392(4), 361-371. https://doi.org/10.1056/nejmoa2406674
Vancouver
Ruff CT, Patel SM, Giugliano RP, Morrow DA, Hug B, Kuder JF, et al. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. New England Journal of Medicine. 2025;392(4):361-371. doi:10.1056/nejmoa2406674
BibTeX
@article{Ruff2025,
author = {Ruff, Christian T and Patel, Siddharth M and Giugliano, Robert P and Morrow, David A and Hug, Bruce and Kuder, Julia F and Goodrich, Erica L and Chen, Shih-Ann and Goodman, Shaun G and Joung, Boyoung and Kiss, Robert G and Spinar, Jindrich and Wojakowski, Wojciech and Weitz, Jeffrey I and Murphy, Sabina A and Wiviott, Stephen D and Parkar, Sanobar and Bloomfield, Daniel and Sabatine, Marc S and AZALEA–TIMI 71 Investigators, AZALEA–TIMI 71 Investigators},
title = {Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {4},
pages = {361--371},
doi = {10.1056/nejmoa2406674}
}
EUVIMED